Effect of a combination of Xuebijing and thymosin α1 on patients with severe pneumonia complicated with sepsis, and its influence on serum inflammatory factors

Yan Li, Suhang Wang, Jing Zhang, Jie Cao*
Department of Respiratory and Critical Care, Tianjin Medical University General Hospital, Tianjin 300052, China
*For correspondence: Email: caojiedr123@outlook.com

Sent for review: 19 February 2022
Revised accepted: 13 June 2022

Abstract

**Purpose:** To investigate the influence of a combination of Xuebijing and thymosin α1 on acute and septic bronchopneumonia (ASB) patients, and the effect of the treatment on inflammation.

**Methods:** Eighty-one (81) ASB patients admitted to Tianjin Medical University General Hospital, Tianjin, China from January 2015 to July 2019 were enrolled in the study. The patients were assigned to control group (n = 41) and a study group (n = 40). The control patients were treated with Xuebijing injection, i.v., while the study group received a combination of Xuebijing injection and thymosin α1 via the subcutaneous route. Patients’ body temperature, heartbeat, white blood cell count, as well as other parameters, including blood gas indices, serum concentrations of IL-6, TNF-α and C-reactive protein (CRP), as well as blood gas indices were determined by enzyme-linked immunosorbent assay (ELISA). Bacterial clearance and therapeutic effectiveness were evaluated pre- and post-treatment.

**Results:** Post-therapy basal temperature, breathing, heartbeat, number of white blood cells and other indices decreased in study patients, relative to control (p < 0.05). Moreover, the levels of hydrogen ion concentration (pH) and arterial carbon dioxide partial pressure (PaCO₂) were significantly lower in study group than in control group (p < 0.05). Patients in the study group had lower serum levels of IL-6, TNF-α and CRP, when compared to control group, while bacterial load was significantly reduced in study subjects, relative to controls (p < 0.05).

**Conclusion:** Combined use of thymosin α1 and Xuebijing is significantly effective in the management of patients suffering from ASB. The combination therapy also improves the hemorheological status of patients. Thus, it is a potential therapeutic strategy for ASB.

**Keywords:** Acute bronchopneumonia, Xuebijing, Thymosin α1, Septicemia, Inflammation

INTRODUCTION

Septicemia results from infection-induced inflammatory reactions such as fever, leukopenia and reduced peripheral resistance, usually leading to low blood pressure (septic shock), organ malfunction and mortality. Indeed, septicemia accounts for approximately 30 % mortality [1]. Septicemia occurs mostly in the aged population. Thus, enhancements in the number of the aged have led to increases in cases of sepsis. In advanced nations, septicemia...
affects 100 out of 100,000 people [2]. Septicemia is a severe response caused by systemic infection, with bronchopneumonia as a leading cause [3]. The etiology of sepsis starts with epitope transfer of antigen-manifesting cells to polymorphonuclear (PMN) leukocytes, macrophages, and T helper lymphocytes (Th), and then the cellular transcription factor NF-KB is activated and enters the nucleus where it forms a conjugate with DNA. Thereafter, the NF-KB-DNA complex triggers apoptosis and induces activation of Th lymphocytes to Th1 cells, leading to up-regulations of inflammation-enhancing TNF-α, and IL-6 [4].

**Xuebijing** injection is a popular anti-sepsis polyherbal TCM containing Angelica sinensis, Ligusticum wallichii, red peony root, Salvia and safflower [5]. It has been reported that Xuebijing suppresses sepsis via mechanisms involving anti-inflammatory, antibacterial, endotoxin-neutralizing effects, thereby enhancing patients' survival [6]. Moreover, when used in combination with standard therapy, it reduces sepsis-related death in subjects with acute bronchopneumonia [7].

The immune-regulatory effects of thymosin α1, a protein hormone, have been reported in in vivo and in vitro studies, and it is an authorized antiviral and anti-cancer drug [8]. A study has shown that the combination of ulinastatin and Xuebijing produced more beneficial effect against septicemia than ulinastatin [9]. The aim of the present research was to investigate the effect of combination of Xuebijing and thymosin α1 in the treatment of sepsis.

**METHODS**

**Background profiles of patients**

Clinical information on 81 subjects with ASB on admission at Tianjin Medical University General Hospital from January 2015 to July 2019 were retrospectively analyzed. The subjects were assigned to 2 groups on the basis of treatment. The control group comprised 41 subjects (25 men and 16 women with mean age of 63.56 ± 5.44 years) treated with Xuebijing injection i.v. The study group had 40 subjects comprised of 26 men and 14 women (with mean age of 64.33 ± 5.32 years) who received a combination of Xuebijing injection and thymosin α1 via the subcutaneous route. The research received approval form the ethical authority of our institution (approval no. 201411112) in line with the principle of the Declaration of Helsinki [10]. Signed written informed permission was obtained from subjects and/or guardians.

The included patients were those who were diagnosed with ASB in line with guidelines for bronchopneumonia in adults in China [11], those who satisfied the 2016 international provisions on treatment of sepsis [12], and patients with intact clinical data. All subjects had impaired immune function or long-term use of ventilators, and they were severe pneumonia patients with long-term illness who often suffered from symptoms such as dyspnea, shortness of breath, asthma, and abnormal body temperature and pulse. The included patients undertook to give full cooperation during the study.

The excluded patients were those who used immunosuppressive drugs within the previous three months, subjects with acute kidney dysfunction and cancer, and those with psychiatric problems, communication problems, and illnesses likely to influence the outcome of the research.

**Treatments**

Following fasting, venous blood was collected from each patient. Serum was separated via centrifugation and preserved by freezing at -80 °C prior to analysis. Serum IL-6, TNF-α and CRP were assayed with ELISA kits. The IL-6 test kits were obtained from Shanghai Ultest Biotechnology Co. Ltd; kits for TNF-α were products of Shanghai Jingshen Bio-Eng. Co. Ltd. (model no. JK-(a)-2161), while the CRP test kits were bought from Shanghai Jingshen Bio-Eng Co. Ltd (model no. JKSJ-1376). The determinations were carried out strictly in accordance with the kit instructions. The index of hydrogen ion concentration (pH) and partial pressure of arterial carbon dioxide (PaCO₂) were measured using ABL80 blood gas analyzer.

Both groups received effective anti-infection drugs. Broad-spectrum potent antibiotics such as carbapenem antibiotics (imipenem/cilastatin, meropenem and ertapenem) were applied. They also received supportive symptomatic treatment such as relieving cough and reducing sputum so as to mitigate asthma. If respiratory failure occurred, mechanical ventilation treatment was provided. Fluid therapy was given to supplement nutrients and hydration. In addition, they received other routine treatments such as regulation of BP and blood glucose, and maintenance of blood pH. Both groups were given Xuebijing (Tianjin CS Pharm. Co. Ltd.), 50 mg at a time, with 100 ml of physiological saline, i.v., for about ½ h, thrice daily. The drug administration lasted for 10 days. In addition, patients in the study group received subcutaneous injection of thymosin α1 (Chengdu DJ Pharm. Co. Ltd) once daily at a
dose of 1.6 mg at a time. The treatment lasted for 10 days.

**Evaluation of parameters/indices**

**General conditions**

The vital signs before and after treatment were recorded and compared between the two groups.

**Blood gas indices**

A blood gas analyzer [model: ABL80 series; Radiometer Medical Equipment (Shanghai) Co., Ltd.] was used to determine the pH and PaCO$_2$ of patients before and after treatment, and statistical analysis was used to compare the values.

**Levels of inflammatory factors**

The serum levels of IL-6, TNF-α and CRP were assayed with ELISA. The IL-6 test kits were purchased from Shanghai Uittest Biological Technology Co. Ltd.; TNF-α kits were products of Shanghai Jingsheng Bioengineering Co. Ltd. (model no. JK-(a)-2161) and the CRP test kits were purchased from Shanghai Bio-Eng. Co. Ltd., (model no. JKSJ--1376). The determination was carried out strictly in accordance with the kit instructions. The levels of inflammatory factors were compared between the two groups.

**Bacterial clearance**

Bacterial clearance (BC) in both groups was monitored. The bacterial clearance (BC) was calculated as the sum of the no. of cleared cases, no. of hypothetical cases, and no. of replacement cases, divided by the total no. of patients, expressed as a percentage.

**Treatment effectiveness**

If respiration, body temperature, heartbeat and white blood cell count were normalized, the patients were deemed cured. If there was marked improvement in health, but one of these indexes was not normalized, the treatment was regarded as markedly effective. If there was marked improvement in the patient's condition, but these three indexes were not improved significantly, the treatment was deemed effective. However, if the patient's condition was unchanged or even aggravated, the treatment was regarded as ineffective. Total treatment effectiveness (TTE) was calculated using Eq 2.

$$TTE(\%) = \left(\frac{CR + ME + E}{T}\right) \times 100 \quad \text{(2)}$$

where $TTE$ = total treatment effectiveness; $CR$ = population of cured subjects; $ME$ = population of markedly effective treatments; $E$ = population of effective treatments; $T$ = total population of patients.

**Statistical analysis**

Results were processed with SPSS 24.0 software, while graphics were generated using GraphPad Prism 7. Enumeration results are presented as percentage (%), and $\chi^2$ test was used for 2-group comparison. All measured results are presented as mean ± SD, and t-test was employed for comparing data within a group. Values of $p < 0.05$ were considered as indicative of statistical significance.

**RESULTS**

**Clinical profile of patients**

Table 1 shows that baseline data were comparable in the two groups ($p > 0.05$).

**Body temperature, respiration, heart rate, leukocytes before and after treatment**

There were no significant differences in the levels of these indexes, including the number of leukocytes between the two groups prior to treatment. However, after treatment, these indexes, including the number of leukocytes in both groups were lower than those before treatment, with lower levels of indexes in the study group than in the control group ($p < 0.05$; Table 2).

**Blood gas indices**

Values of the blood gas indexes were comparable in the two groups before treatment. However, after treatment, there were reduced PaCO$_2$ and pH levels in both groups, with lower levels in the study group than in the control group ($p < 0.05$; Table 3).

**Blood levels of CRP, IL-6 and TNF-α**

The levels of these factors were comparable in the two groups before treatment. However, post-treatment, there were decreased amounts of IL-6, TNF-α and CRP in both groups, relative to pre-treatment values, with lower levels in the study group than in the control group ($p < 0.05$). These data are shown in Table 4.
Table 1: Clinical data for patients in both groups

| Variable                  | Study patients (40) | Control patients (41) | t (or F) | P-value |
|---------------------------|---------------------|-----------------------|----------|---------|
| Sex                       | Male                | 26                    | 25       | 0.141   |
|                           | Female              | 14                    | 16       | 0.709   |
| Age (years)               | 64.33±5.32          | 63.56±5.44            | 0.644    | 0.522   |
| BMI (kg/m²)               | 22.47±2.83          | 22.15±2.62            | 0.528    | 0.599   |
| Place of residence        | City                | 31                    | 32       | 0.004   |
|                           | Rural               | 9                     | 9        | 0.953   |
| Nationality               | Han                 | 36                    | 34       | 0.863   |
|                           | Minority            | 4)                    | 7        | 0.353   |
| Smoking history           | Yes                 | 29                    | 31       | 0.102   |
|                           | No                  | 11                    | 10       | 0.749   |
| Drinking history          | Yes                 | 21                    | 23       | 0.106   |
|                           | No                  | 19                    | 18       | 0.745   |
| Marital status            | Married             | 37                    | 39       | 0.240   |
|                           | Unmarried           | 3                     | 2        | 0.624   |
| Family history            | Yes                 | 18                    | 17       | 0.103   |
|                           | No                  | 22                    | 24       | 0.748   |

Table 2: Comparison of pre- and post-treatment body temperature, breathing, heartbeat and white blood cell count between the 2 groups

| Index                      | Study (n=40) | Control (n=41) | t     | P-value |
|----------------------------|--------------|----------------|-------|---------|
| Body temperature (℃)       | Before        | 38.02±1.03     | 38.09±1.05 | 0.303 | 0.763   |
|                           | After         | 37.10±0.51*    | 37.52±0.59* | 3.424 | < 0.001 |
| Respiration (times/min)    | Before        | 27.13±3.21     | 26.94±3.33 | 0.261 | 0.795   |
|                           | After         | 20.75±1.82*    | 23.65±2.03* | 6.764 | < 0.001 |
| Heart rate (times/min)     | Before        | 104.83±13.21   | 105.04±16.81 | 0.062 | 0.950   |
|                           | After         | 75.86±11.69*   | 81.94±12.43* | 2.267 | 0.026   |
| Number of leukocytes       | Before        | 17.13±7.43     | 16.97±7.29 | 0.098 | 0.922   |
|                           | After         | 6.97±2.31*     | 10.54±3.64* | 5.255 | < 0.001 |

*P < 0.05, significant difference before and after treatment in the same group

Table 3: Comparison of blood gas indexes before and after treatment between the two groups

| Index                      | Study group (n=40) | Control group (n=41) | t     | P-value |
|----------------------------|--------------------|----------------------|-------|---------|
| pH                         | Before treatment   | 7.87±0.08            | 7.88±0.07 | 0.599 | 0.551   |
|                           | After treatment    | 7.05±0.05            | 7.31±0.07 | 19.194 | < 0.001 |
| PaCO₂ (mm Hg)              | Before treatment   | 54.29±5.24           | 53.98±5.21 | 0.267 | 0.790   |
|                           | After treatment    | 35.18±5.29           | 39.23±5.33 | 3.488 | 0.001   |
| t                          | Before treatment   | 16.232               | 12.672   | < 0.001 |
|                           | After treatment    | < 0.001              | < 0.001  | < 0.001 |
Table 4: Comparison of serum IL-6, TNF-α and CRP levels before and after treatment between the 2 groups

| Index     | Study group (n=40) | Control group (n=41) | t      | P-value |
|-----------|--------------------|----------------------|--------|---------|
| IL-6 (ng/L) Before treatment | 103.62±24.04 | 102.74±23.48 | 0.167 | 0.868   |
|           | After treatment    | 52.67±16.51         | 68.93±17.62 | 4.283 | < 0.001 |
| t         | 11.049             | 7.375                |        |         |
| P-value   | < 0.001            | < 0.001             |        |         |
| TNF-α (ng/L) Before treatment | 100.93±21.37 | 99.83±21.43 | 0.231 | 0.818   |
|           | After treatment    | 55.21±15.02         | 69.75±14.97 | 4.363 | < 0.001 |
| t         | 11.070             | 7.368                |        |         |
| P-value   | < 0.001            | < 0.001             |        |         |
| CRP (mg/L) Before treatment | 72.88±15.65 | 71.65±15.54 | 0.355 | 0.724   |
|           | After treatment    | 31.21±9.12          | 38.12±8.65 | 3.499 | 0.001   |
| t         | 14.550             | 12.072               |        |         |
| P-value   | < 0.001            | < 0.001             |        |         |

Table 5: Post-treatment bacterial clearance levels in the 2 groups

| Bacterial clearance efficiency | Study group (n=40) | Control group (n=41) | F  | P-value |
|-------------------------------|--------------------|----------------------|----|---------|
| Clearance                     | 20                 | 14                   |    |         |
| Hypothetical clearance        | 11                 | 9                    |    |         |
| Replacement                   | 4                  | 5                    |    |         |
| No clearance                  | 4                  | 6                    |    |         |
| Reinfection                   | 1                  | 7                    |    |         |
| Clearance rate                | 87.50%             | 68.29%               | 4.322 | 0.038  |

Table 6: Effectiveness of treatments in the two groups

| Group         | Cure | Markedly effective | Effective | Ineffective | Total effectiveness (%) |
|---------------|------|--------------------|-----------|-------------|-------------------------|
| Study (n = 40)| 7    | 15                 | 14        | 4           | 90.00                   |
| Control (n = 41)| 4   | 12                 | 13        | 12          | 70.73                   |
| F             | 3.742|                    |           |             |                         |
| P             | 0.029|                    |           |             |                         |

Bacterial clearance

The results in Table 5 show that the bacterial clearance of the study group was 87.50 %, while that of the control group was 68.29 %.

Clinical effectiveness

The results presented in Table 6 show that total treatment effectiveness in study patients (90.0 %) was markedly superior to that in control patients (70.73 %).

DISCUSSION

An imbalance between levels of pro- and anti-inflammatory factors in subjects with acute bronchopneumonia eventually leads to sepsis. Sepsis causes impairment of immune function through reduction in the population of immune cells. It has been reported that the suppression of immunity in septicemia subjects is linked to lymphocytes [13]. Xuebijing is a polyherbal TCM that enhances blood flow and reduces blood stasis [14]. Research have demonstrated that Xuebijing and Thymosin α1 function as immune-regulatory and anti-inflammatory agents [15,16]. In a study, it was shown that thymosin α1 produced good effectiveness in septicemia patients [17]. As already stated, Xuebijing and thymosin α1 inhibit inflammation and regulate immune response. In the present research, there were lower body temperature, breathing rate, heartbeat and white blood cell population in study patients than in controls, post-treatment. Moreover, the study group had markedly superior total treatment effectiveness, relative to controls, indicating enhanced efficacy of the combined treatment. It has been reported the level of CRP, the most crucial index of inflammation and immune function, is higher in ASB subjects than in healthy controls [18]. The combined use of Xuebijing and thymosin α1 in this investigation resulted in markedly decreased concentrations of CRP, IL-6 and TNF-α. This demonstrates effective regulation of immune function and inflammation in the
patients. A similar result was obtained in a previous study which showed that Xuebijing markedly down-regulated TNF-α and IL-6 in a septicemic mouse model [19].

Prior to drug administration, blood rheology parameters were comparable in the study and control groups. However, blood rheology in the 2 groups were reduced, relative to the corresponding pre-treatment values, but were lower in study subjects than in control subjects. Thus, the combined treatment was efficacious in mitigating bronchopneumonia symptoms of patients and normalizing blood gas and pro-inflammatory factors in patients, without undesirable drug-related adverse events. This is because Xuebijing inhibits the assemblage platelets, accelerates blood circulation, increases vascular tone, improves oxygen levels, removes enzymes catalyzing bradykinin generation such as hydrolase and protease, repairs gaps in cells lining the blood vessels, reduces vascular porosity, and reduces levels of pro-inflammatory mediators [20]. Thymosin α1 stimulates the presentation of antigens on macrophage receptors, thereby enhancing antigen neutralization potential and significantly improving immunity and preventing inflammatory response in septicemic subjects.

Limitations of the study

This study has some shortcomings. It used a small sample size, and it lacked effective statistical analysis based on big data due to limited experimental conditions. Besides, results demonstrated that thymosin α1 reduced death in sepsis subjects, but a follow-up after intervention was not conducted in this study. Therefore, in subsequent studies using a larger sample size, the patients will be followed up and investigated to constantly improve the experiments and obtain more validated research results.

CONCLUSION

Thymosin α1, in combination with Xuebijing injection, significantly ameliorates ASB, improves blood gas pH and PaCO₂, eliminates septicemia and bacteria, and lowers the concentrations of serum pro-inflammatory factors. Therefore, the combination treatment is a potential therapeutic strategy for ASB.

DECLARATIONS

Acknowledgements

None provided.

Funding

None provided.

Ethical approval

None provided.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

We declare that this work was done by the authors named in this article, and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Yan Li and Jie Cao conceived and designed the study, and drafted the manuscript. Yan Li, Suhang Wang, Jing Zhang and Jie Cao collected, analyzed and interpreted the experimental data. Yan Li and Suhang Wang revised the manuscript for important intellectual contents. All authors read and approved the final manuscript.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med 2015; 3(1): 53-60.
2. Zhang W, Jia J, Liu Z, Si D, Ma L, Zhang G. Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0. BMC Pulm Med 2019; 19(1): 93.
3. Yang X, Qiao C, Zheng C, Deng Q. Antioxidant and anti-inflammatory effect of ligustilide on sepsis-induced acute
kidney injury via TLR4/NF-κB and Nrf2/HO-1 signaling. Trop J Pharm Res 2021; 20(1): 83-87.
4. Liu F, Wang HM, Wang T, Zhang YM, Zhu X. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis 2016; 16: 488.
5. Chen S, Dai G, Hu J, Rong A, Lv J, Su L, Wu X. Discovery of Xuebijing injection exhibiting protective efficacy on sepsis by inhibiting the expression of HMGB1 in septic rat model designed by cecal ligation and puncture. Am J Ther 2016; 23(6): e1819-e1825.
6. Ma ST, Liu PX, Long W, Yu J, Xu Y. Effects of the Multi-Target Capability of Xuebijing and Its Inflammatory Pharmacodynamic Material Basis. Acta Physico-Chimica Sinica 2009; 25: 2080-2086.
7. Song Y, Yao C, Shang H, Yao X, Bai C. Intravenous infusion of Chinese medicine Xuebijing for patients with severe pneumonia: a multicenter, randomized, double-blind controlled trial. Lancet 2017; 390: S34.
8. Mandaliti W, Nepravishta R, Pica F, Valibona PS, Garaci E, Paci M. Thymosin α1 Interacts with Hyaluronic Acid Electrostatically by its Terminal Sequence LKEKK. Molecules 2017; 22(11): 1843.
9. Chen G, Gao Y, Jiang Y, Yang F, Li S, Tan D, Ma Q. Efficacy and safety of Xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis. Front Pharmacol 2018; 9: 743.
10. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4.
11. Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, Xu JF, Zhang J, Chen Y, Shen N. et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J 2018; 12(4): 1320-1360.
12. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar; 43(3): 304-377.
13. Branco RG, Garcia PC. Ferritin and C-Reactive Protein as Markers of Systemic Inflammation in Sepsis. Pediatr Crit Care Med 2017; 18(2): 194-196.
14. Jiang Y, Zou L, Liu S, Liu X, Chen F, Liu X, Zhu Y. GC/MS-based metabolomics approach reveals effects of Xuebijing injection in CLP induced septic rats. Biomed Pharmacother 2019; 117: 109163.
15. He XD, Wang Y, Wu Q, Wang HX, Chen ZD, Zheng RS, Wang ZS, Wang JB, Yang Y. Xuebijing Protects Rats from Sepsis Challenged with Acinetobacter baumannii by Promoting Annexin A1 Expression and Inhibiting Proinflammatory Cytokines Secretion. Evid Based Complement Alternat Med 2013; 2013: 804940.
16. Pica F, Gaziano R, Casaliniuovo IA, Moroni G, Buè C, Limongi D, D'Agostini C, Tomino C, Perricone R, Palamara AT, Sinibaldi Valibona P, Garaci E. Serum thymosin alpha 1 levels in normal and pathological conditions. Expert Opin Biol Ther 2018; 18(sup1): 13-21.
17. Li J, Chen X, Pan Z, Wu H, Ding H, Li M, Deng T, Su L. Modulation of interleukin-8 and interleukin-10 in serum by thymosin alpha1 in septic patients. Medical Journal of Chinese People's Liberation Army 2018; 43: 939-942.
18. Vashist SK, Venkatesh AG, Marion Schneider E, Beaudoin C, Luppa PB, Luong JH. Bioanalytical advances in assays for C-reactive protein. Biotechnol Adv 2016; 34(3): 272-290.
19. Chen X, Feng Y, Shen X, Pan G, Fan G, Gao X, Han J, Zhu Y. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis. J Ethnopharmacol 2018; 211: 358-365.
20. Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. Expert Rev Respir Med 2014; 8(5): 587-596.